Efficacy of Zhuyu Pill Intervention in a Cholestasis Rat Model: Mutual Effects on Fecal Metabolism and Microbial Diversity

Han Yu¹, Chao Liu¹, Fenghua Zhang¹, Jianfei Wang², Jun Han³, Xin Zhou¹, Yueqiang Wen¹* and Tao Shen¹*

¹School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China, ²Department of Nephrology, South of Guang’anmen Hospital, Beijing, China, ³Department of Reader Service and Culture Education, Chengdu University of Traditional Chinese Medicine, Chengdu, China

Cholestasis is a clinical condition resulting from impaired bile flow. Currently, patients with cholestasis face several barriers in seeking diagnosis and treatment. Zhuyu Pill (ZYP) is an ancient classic formula of the Coptis-Evodia herb couples (CEHC), and has been used for cholestasis treatment in the clinic, however, its underlying biological activity in cholestasis remain to be clarified. In this study, an α-naphthyl-isothiocyanate (ANIT, 50 mg/kg)-induced rat model of cholestasis was treated with ZYP. Serum biochemical indices and histopathological evaluation was performed, together with the metabolomics analyses of feces and 16S rDNA sequencing of the fecal microbiota. We evaluated the anti-cholestatic activity of ZYP and investigated the mechanisms underlying its correlation with fecal microbiota and fecal metabolite regulation. The relationships between biochemical indices and changes in gene expression associated with liver injury, levels fecal metabolites, and composition of fecal microbiota were analyzed. The results showed that both high (1.2 g/kg) and low (0.6 g/kg) doses of ZYP could effectively improve biochemical parameters in the blood of cholestasis-induced rat models; the intervention effect of high dose ZYP was superior to that of lower dose ZYP. Based on a metabolomics test of fecal samples, significantly altered metabolites in the ANIT and ZYP treatment group were identified. In total, 734 metabolites were differentially expressed, and whose biological functions were mainly associated with amino acid metabolism, steroid hormone biosynthesis, and bile secretion. In addition, sequencing of the 16S rDNA unit in fecal samples revealed that the ZYP could improve the fecal microbiota dysbiosis that ANIT had induced. Therefore, we conclude that ANIT altering of blood biochemical and metabolic profiles and of fecal microbiota could effectively be alleviated with ZYP treatment. This study contributes to the “TCM wisdom” applied in clinical diagnosis and treatment of cholestasis.

Keywords: cholestasis, zhuyu pill, fecal metabolism, fecal microbial diversity, mutual effects

Abbreviation: CEHC, Coptis-Evodia herb couple; TCM, Traditional Chinese medicine; ZYP, Zhuyu Pill; ZYP-, ZYP-low dose; ZYP+, ZYP-high dose.
INTRODUCTION

In recent years, changes in dietary habits and living environments, the incidence of liver diseases, and associated complications represent a major healthcare burden in China (Tang et al., 2017). Cholestasis, which can be caused by pre-existing medical conditions including infections, drug treatment, and metabolic or genetic disorders (Boyer, 2007), is classified as intrahepatic, involving mainly liver parenchymal cells, or extrahepatic, involving any excretory block outside of the liver (Chatterjee et al., 2020). A cross-sectional study of cholestasis in 1000 patients in China demonstrated that, the biochemical parameters in the blood of intrahepatic cholestasis, such as alkaline phosphatase (ALP) and γ-glutamyl transferase (γ -GT), were higher than the upper limit of normal, and the risk and severity of liver damage in these patients were markedly increased (Cheng et al., 2015). Due to the lack of timely treatment, liver cells, including portal myofibroblasts and hepatic stellate cells, are hyperactivated and cholestasis leads to fibrosis and even cirrhosis (Allen et al., 2011). Currently available therapeutic options of cholestasis are limited.

Bile acids such as ursodeoxycholic acid (UDCA) and chenodeoxycholic acid (CDCA) are used routinely for the dissolution of gallstones and have recently been proposed as treatment for chronic cholestatic liver disease (Crosignani et al., 1996; Beuers et al., 1998; Sasaki et al., 2001). However, approximately one-third of patients achieve little or no response to UDCA treatment (Itakura et al., 2004; Lane and Murray, 2017). Traditional Chinese medicine (TCM) has been used to treat liver and digestive disease in China since ancient times. *Coptidis rhiza* (Coptis, Huanglian in Chinese) and *Evodia fructus* (Evodia, Wuzhuyu in Chinese) is a well-known herbal combination usually used to treat liver and digestive diseases. *Zuojin Pill* (ZJP), usually in a mixture ratio 6:1, g/g and *Zhuyu Pill* (ZYP, usually in mixture ratio 1:1, g/g) are the ancient classic formulas of the Coptis-Evodia herb couple (CEHC). To date, studies have shown that ZJP can influence the metabolism of venlafaxine (Cheng et al., 2011), the brain-gut axis, and cell proliferation, and its therapeutic effects in liver and stomach diseases have been reported (Wang et al., 2015; Guo et al., 2019). These results support the CEHC combination for the treatment of liver and digestive diseases. However, compared with ZJP, less attention has been paid to ZYP and the efficacy and effector mechanisms of ZYP remain to be examined.

TCM is a complex therapy involving multiple targets with synergistic or antagonistic interactions among its components. In contrast to the Western medicine notion of “one target, one drug,” TCM is characterized by “multi-component, multi-target, and multi-pathway” activity; this concept of the holistic view is emphasized in the theory of TCM. Metabonomics is an important technique in systems biology (Kaddurah-Daouk et al., 2008). It is the study of the composition and variation of metabolic groups, and thereby reveals the overall metabolic response and dynamic changes induced under different conditions. Metabonomics has been used to study the organism as a whole, which is consistent with the holistic view of TCM and the concept of syndrome differentiation and treatment (Wang et al., 2017). Because the modernization of TCM is becoming necessary and urgent (Li et al., 2008), metabonomics represents a modern technology with a great potential toward understanding the efficacy and mechanism of TCM (Sun et al., 2012; Wang et al., 2020).

Intestinal microecology not only comprises the gut microbiota, but also numerous gut microbiota metabolites (Chen C. et al., 2019). Hence, the gut microbiota can be defined as a “metabolic organ” (Wei et al., 2020). Recent studies have shown that, bile acids (BAs) are host-derived and microbial-modified metabolites that regulate both the gut microbiome and host metabolism (Islam et al., 2011; Wahlstrom et al., 2016; Kemis et al., 2019). The fecal metabolome provides unique information on the metabolic interactions between the fecal microbiota, diet, and host. Combined with 16S next-generation-sequencing, the metabolome can provide a comprehensive phenotype of the host-microbiome interplay (Yang et al., 2019).

In this study, an animal model of cholestasis was induced using α-naphthylisothiocyanate (ANIT) (Hill et al., 1999) and the pharmacodynamic effects were evaluated by changes in serum biochemical indices, liver histopathology, liver inflammation, apoptosis, and gene expression associated with fibrosis. Differential metabolites levels were identified using liquid chromatography-mass spectrometry (LC-MS) with an untargeted metabolomics approach and the abundance of fecal microbiota was analyzed using 16S ribosomal RNA (16S rRNA). In addition, to characterizing the mechanisms of ZYP activity in regulating cholestasis, we aimed: 1) to explore the effects of ZYP on improving liver function; 2) to measure the composition of the fecal microbiota in order to identify differential metabolites induced of ZYP in cholestasis; and 3) to correlate the results of untargeted metabolomics and the diversity of fecal microbes to better define the underlying biological mechanisms involved in the anticholestatic activity of ZYP. These findings will enhance our understanding of pathogenic mechanisms of cholestasis and will provide a new therapeutic option for the treatment of cholestasis.

MATERIALS AND METHODS

Reagents

ANIT was purchased from Sigma-Aldrich Co. (St. Louis, MO, United States). *Coptidis rhiza* and *Evodia fructus* were purchased from Beijing Tongrentang Science and Technology Development Co. Ltd (Beijing, China). Water, methanol, acetonitrile, and formic acid were purchased from the CNW Technologies GmbH (Düsseldorf, Germany). L-2-chlorophenylalanine was from Shanghai Hengchuang Biotechnology Co., Ltd. (Shanghai, China). All chemicals and solvents were analytical or HPLC grade.

Preparation and Quality Control of ZYP

Zhuyu Pill was prepared as follows: *Coptidis rhiza* (6 g), and *Evodia fructus* (6 g) were weighed and placed in 120 ml of distilled water (1:10, w/v) for 6 h. These samples were then boiled twice, for 45 min each time.
To determine the active constituents, two main alkaloids (berberine and coptisine) in ZYP were analyzed by HPLC using the Agilent 1260 Infinity II (Agilent Technologies Inc., California, United States). The chromatographic separation was carried out with a Welch Ultimate XB-C18 Column (4.6 mm × 250 mm, 5 µm, Maryland, United States) at a column temperature of 30°C. The linear-gradient mobile phase consisted of mobile phase A (50 mM monopotassium phosphate+0.4% sodium heptane sulfonate, pH = 4) and mobile phase B (pure methanol). The gradient of the mobile phase was utilized (0–15 min, 95% A, 5% B; 15–40 min, 50% A, 50% B; 40–55 min, 30% A, 70% B, 55–60 min, 95% A, 5% B), and a flow rate of 1.0 ml/min was adopted. The detection wavelength was set as (0–44 min, 345 nm; 44–80 min, 260 ± 20 nm). The HPLC analysis showed that the contents of berberine and coptisine in ZYP were 33.2 and 13.4 mg/g, respectively.

**Animals and Treatments**

A total of 24 male Sprague-Dawley rats (7–8 wk old; weighing 260 ± 20 g) were obtained from Beijing HFK Bioscience Co., Ltd. (Beijing, China; certification no. SCXK-JING 2019-0008). All animals were allowed to acclimate for 1 wk prior to the experiments and were maintained at a constant temperature (25 ± 2°C) and 50% humidity with a 12-h/12-h light/dark cycle; all the rats had access to water and food ad libitum.

An overview of the experimental design is presented in Table 1. The animals were randomly divided into four groups of six rats each, including the control, model, ZYP-low dose (ZYP−) and ZYP-high dose (ZYP+) groups. The rats in the normal group served as the normal control and were given distilled water each day and treated with vehicle (olive oil) alone. The model group was treated with 50 mg/kg ANIT dissolved in an equal volume of olive oil by gavage (Chen et al., 2016). ZYP was given to the treatment groups at doses of 0.6 (ZYP−), 1.2 (ZYP+) g/kg body weight, respectively, six times before and four times after they were treated with 50 mg/kg ANIT by gavage. In this study, ZYP doses that were adopted were based on the maximum recommended clinical dose (MRCD, 12 g/60 kg/day).

**ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

The study protocol was performed in strict accordance with the recommendations of the Guidelines for the Care and Use of Laboratory Animals of the Ministry of Science and Technology of China, and was approved by Ethics Committee of Chengdu University of Traditional Chinese Medicine (Chengdu, China). All efforts were made to minimize animal suffering.

**Sample Collection, Liver Function, and Gene Expression Assays**

The rats were provided with standard chow and water on completion of treatments. At least two fresh stools pellets were obtained from each rat after the last ZYP administration. Samples were placed in sterile conical tubes and immediately frozen at −80°C until further metabolic profiling and microbial community analysis, respectively.

According to pilot experiments, the rats were then fasted for 12 h, and were then euthanized 12 h after the last ZYP administration. Blood samples were collected from the inferior vena cava and the liver was excised from each rat immediately after sacrifice. The blood samples were collected and centrifuged at 3500 × g and 4°C for 15 min to obtain the serum. The serum total cholesterol (TC; cat. no. 105-000448-00), aspartate aminotransferase (AST; cat. no. 105-000443-00), alanine aminotransferase (ALT; cat. no. 105-000442-00), γ-glutamyl transpeptidase (γ-GT; cat. no. 105-000445-00), total bilirubin (TBIL; cat. no. 0041-30-53548) and total bile acid (TBA; cat. no. 105-000456-00) levels were detected using a fully automatic biochemical analyzer (BS-240VET), which together with all assay kits were purchased from Mindray Bio-medical Electronics Company (Mindray Bio-medical Electronics Company, Ltd, Shenzhen, China).

Total RNA of liver samples was extracted by mirVana™ RNA Isolation Kit (Cat. AM1561; Thermo Fisher Scientific, Waltham, MA, United States). The expression of tumour necrosis factor alpha (TNF-α), transforming growth factor beta 1 (TGF-β1), interleukin-10 (IL-10), metalloproteinase inhibitor 1 (TIMP-1), Glutamate cysteine ligase catalytic subunit (GCLC), Glutamate cysteine ligase regulatory subunit (GCLM), B-cell lymphoma 2 (BCL2) and BCL2-associated X (BAX) were detected by Quantitative Real-time PCR (qPCR). Quantification was performed using a two-step reaction process: reverse transcription (RT) and PCR. Each RT reaction (10 µl total) consisted of 0.5 µl of RNA, 2 µl of 5×TransScript All-in-one SuperMix for qPCR, and 0.5 µl of gDNA Remover. Reactions were performed in a GeneAmp® PCR System 9700 (Thermo Fisher Scientific) for 15 min at 42°C and then 5 s at 85°C. The RT reaction mix was then diluted 10× in nuclease-free water and held at −20°C.

Real-time PCR was performed using a LightCycler® 480 II Real-time PCR Instrument (Roche, Basel, Switzerland) with a

| Group | week old | 1–7 days | 8–13 days | 14 days | 15–18 days | 19 days |
|-------|----------|----------|-----------|--------|------------|--------|
| Control | 7–8 | acclimate | distilled water | Olive Oil | distilled water | Sacrifice |
| Model | 7–8 | acclimate | distilled water | 50 mg/kg ANIT | distilled water | Sacrifice |
| ZYP− | 7–8 | acclimate | 0.6 g/kg ZYP | 50 mg/kg ANIT | 0.6 g/kg ZYP | Sacrifice |
| ZYP+ | 7–8 | acclimate | 1.2 g/kg ZYP | 50 mg/kg ANIT | 1.2 g/kg ZYP | Sacrifice |

**TABLE 1 | The schematic diagram of the animal experimental design.**

The study protocol was performed in strict accordance with the recommendations of the Guidelines for the Care and Use of Laboratory Animals of the Ministry of Science and Technology of China, and was approved by Ethics Committee of Chengdu University of Traditional Chinese Medicine (Chengdu, China). All efforts were made to minimize animal suffering.
TABLE 2 | mRNA primer sequences.

| Gene Symbol | Forward primer (5'-3') | Reverse primer (5'-3') | Product length (bp) | Tm (°C) |
|-------------|------------------------|------------------------|---------------------|---------|
| TNF-α       | 5'-CCCTGGTATGAGCCCATGTA-3' | 5'-CGGACTCCGGTATGTCTAAAGTA-3' | 106                | 60      |
| TGF-β       | 5'-TACATGGATGATCAGTGGGAAAG-3' | 5'-TACATGGTCTCTGGGAAGTCTG-3' | 97                 | 60      |
| IL-10       | 5'-CTTCTAGGATGCTTGGTGTCG-3' | 5'-TTCCTGGGCGGATGCTTCTC-3' | 95                 | 60      |
| TIMP-1      | 5'-GATTATGGTCTAAGTGCTGCA-3' | 5'-GATTAGTGGATGATCAGTGGGAAAG-3' | 81                | 60      |
| GCLC        | 5'-CCCTCCTTTCTTCAACAGCG-3' | 5'-TGGCACATTGATGACAACC-3' | 104               | 60      |
| GCLM        | 5'-GTGTTAGCGACACAGATT-3' | 5'-TGCGCTGAAAGACAGTTCC-3' | 93                 | 60      |
| BCL2        | 5'-GATTGGGCTTCCCTTTGAGT-3' | 5'-GACAGAGGAGCTTGGTCC-3' | 90                 | 60      |
| BAX         | 5'-TGGACTGGACCTTGGAGAAGA-3' | 5'-GTCGATTCCATCGCGAAT-3' | 85                 | 60      |
| ACTB        | 5'-GCGGATGTAACACCTTCTG-3' | 5'-TATGCCTATCCAGGCGAAC-3' | 72                 | 60      |

10 µl PCR reaction mixture that included 1 µl of cDNA, 5 µl of 2×PerfectStartTM Green qPCR SuperMix, 0.2 µl each of forward and reverse primers, and 3.6 µl of nuclease-free water. Reactions were incubated in a 384-well optical plate (Roche, Basel, Switzerland) at 94°C for 30 s, followed by 45 cycles of 94°C for 5 s and 60°C for 30 s. Each sample was analysed in triplicates. At the end of the PCR cycles, melting curve analysis was performed to validate the specific generation of the expected PCR product. The primer sequences were designed in the laboratory and synthesised by TsingKe Biotech based on the mRNA sequences obtained from the NCBI database (Table 2).

Histological Analysis of Liver Damage

Liver tissues were excised and fixed in 10% phosphate-buffered formalin. Fixed issues were cut into 1 × 1 × 0.3 cm sections. Sections were dehydrated in a gradient alcohol series, and embedded in paraffin wax blocks. The embedded wax blocks were cut into 4–5 µm thick slices. Following dewaxing slides in xylene, the slides were stained with hematoxylin and agitated for 30 s, rinsed in H2O for 1 min, followed by staining with 1% eosin Y solution for 30 s with agitation, all at room temperature (20–25°C). Slides were examined under an Eclipse E100 microscope (NIKON, Tokyo, Japan). The degree of inflammation and necrosis were classified according to the Ishak Scoring System (Ishak et al., 1995; Goodman, 2007).

Sample Preparation for Metabolome Profiling

A 60 mg stool sample was accurately weighed and transferred to a 1.5-ml Eppendorf tube. Two small steel balls were added to the tube. A 20 µl volume of internal standard (2-chloro-l-phenylalanine in methanol, 0.3 mg/ml) and 600 µl extraction solvent with methanol/water (4/1, v/v) were added to each sample. Samples were stored at –20°C for 5 min and then ground at 60 Hz for 2 min, ultrasonicated at ambient temperature (25–28°C) for 10 min, stored at –20°C for 30 min. The extract was centrifuged at 9800 × g, 4°C for 10 min and then, a 300 µl sample of the supernatant in a brown and glass vial was dried in a freeze concentration centrifuged dryer. Next, 400 µl of a mixture of methanol and water (1/4, v/v) were added to each sample, and samples were vortexed for 30 s, ultrasonicated for 3 min, and then placed at –20°C for 2 h. Finally, samples were centrifuged at 9800 × g, at 4°C for 10 min and the supernatants (150 µl) from each tube were collected using crystal syringes, filtered through 0.22 µm microfilters, and transferred to LC vials. The vials were stored at –80°C until LC-MS analysis. QC samples were prepared by mixing aliquots of the all samples to form a pooled sample. All extraction reagents were precooled at –20°C before use.

LC-MS Analysis

A Dionex Ultimate 3000 RS UHPLC system fitted with Q-Exactive quadrupole-Orbitrap mass spectrometer equipped with heated electrospray ionization (ESI) source (Thermo Fisher Scientific) was used to analyze the metabolic profiles in both the ESI positive and ESI negative ion modes. An ACQUITY UPLC HSS T3 (100 mm × 2.1 mm, 1.8 µm) was employed in both positive and negative modes. The binary gradient elution system consisted of (A) water (containing 0.1% formic acid, v/v) and (B) acetonitrile (containing 0.1% formic acid, v/v) and separation was achieved using the following gradient: 5–20% B over 0–2 min, 20–60% B over 2–4 min, 60–100% B over 4–11 min, the composition was held at 100% B for 2 min, then 13–13.5 min, 100–5% B, and 13.5–14.5 min holding at 5% B. The flow rate was 0.35 ml/min and column temperature was 45°C. All the samples were kept at 4°C during the analysis. The injection volume was 2 µl.

The mass range was from m/z 100 to 1000. The resolution was set at 70,000 for the full MS scans and 17,500 for MS/MS scans. The collision energy was set at 10, 20, and 40 eV. The mass spectrometer operated as follows: spray voltage, 3800 V (+) and sheath gas flow rate, 35 arbitrary units; Capillary temperature, 320°C.

The QCs were injected at regular intervals (every four samples) throughout the analytical run to provide a set of data from which repeatability could be assessed. Raw sequence data of metabolomics have been uploaded to Metabolights (https://www.ebi.ac.uk/metabolights/) and are available through accession number (MTBL52721).

Data Preprocessing and Statistical Analysis

The acquired LC-MS raw data were analyzed using the Progenesis QI software (version 2.3; Nonlinear Dynamics, Newcastle, United Kingdom), based on a self-built databases (the EMDB database, is specific for human and animals species, and was set up as an exclusive metabolite database containing data for over 3600 metabolites, including amino acids, lipids, nucleotides,
carbohydrates, vitamins and cofactors, and hormones. It also includes information on metabolite structure and mass spectrum data to address metabolomics biology). The following parameters were used: precursor tolerance was set 5 ppm, product tolerance was set 10 ppm, and retention time (RT) tolerance was set 0.02 min. Internal standard detection parameters were deselected for peak RT alignment, isotopic peaks were excluded for analysis, and the noise elimination level was set at 10.00, the minimum intensity was set to 15% of the base peak intensity. An Excel file was obtained containing three-dimensional data sets including m/z, peak RT, and peak intensities, and RT–m/z pairs were used as the identifier for each ion. The resulting matrix was further reduced by removing any peaks with missing value (ion intensity = 0) in more than 50% of the samples. Positive and negative data were combined data, which was then imported into R ropls package.

Principle component analysis (PCA) and Orthogonal partial least-squares-discriminant analyses (OPLS-DA) were carried out to visualize the metabolic alterations between experimental groups, after mean centering (Ctr) and Pareto variance (Par) scaling, respectively. The Hotelling’s T2 region, shown as an ellipse in the score plots of the models, defined the 95% confidence interval (CI) of the modeled variation. Variable importance in the projection (VIP) ranked the overall contribution of each variable to the OPLS-DA model, and variables with VIP >1 were considered relevant for group discrimination. Default seven-round cross-validation and the 200 response permutation test were applied, with one-seventh of the samples excluded from the mathematical model in each round to avoid overfitting.

The differential metabolites were selected based on the combination of a statistically significant threshold of variable influence on projection (VIP) values obtained from the OPLS-DA model and p-values derived from a two-tailed Student’s t-test using the normalized peak areas, where metabolites with VIP > 1.0 and p < 0.05 were considered as differential metabolites.

DNA Extraction, Library Construction, and Sequencing
Total genomic DNA was extracted using DNA Extraction Kit following the manufacturer’s instructions (Cat.12888; QIAGEN, Dusseldorf, Germany). The DNA concentration was verified with using the NanoDrop and by agarose gel electrophoresis. The DNA genome was used as template for PCR amplification with barcoded primers and TkS Gllex DNA Polymerase (R060B; TaKaRa Bio, Bejing, China). For bacterial diversity analysis, the V3–V4 variable region of the 16S rRNA gene was amplified using primers 343F and 798R (Nossa et al., 2010), using a commercial PCR kit (Cat. 51531; Qiagen).

Amplicon quality was visualized by gel electrophoresis, and amplicons were purified with AMPure XP beads (Cat. A63880; Agencourt), and amplified for another round of PCR. After a second purification with the AMPure XP beads, the final amplicon was quantified using Qubit dsDNA assay kit (Cat. Q32854; Thermo Fisher Scientific). Equal amounts of purified amplicon were pooled for subsequent sequencing based on Novaseq PE250. Raw sequence data were uploaded to the National Center for Biotechnology Information (NCBI) database (https://www.ncbi.nlm.nih.gov/) and are available through accession number (PRJNA720504).

Taxonomical Annotation
Raw sequencing data were exported in FASTQ format. Paired-end reads were then preprocessed using Trimmomatic software (Bolger et al., 2014) to detect and eliminate ambiguous bases (N). Further, low quality sequences were eliminated having an average quality score below 20 using sliding window trimming approach. After trimming, paired-end reads were assembled using FLASH software (version 34.0.0.118) (Reyon et al., 2012). Parameters of assembly were: 10 bp of minimal overlapping, 200 bp of maximum overlapping and a 20% maximum mismatch rate. Sequences were further filtered as follows: reads with ambiguous, homologous sequences or below 200 bp were abandoned; reads with 75% of bases above Q20 were retained; and, reads with chimera were detected and removed. These steps were achieved using QIIME software (version 1.8.0) (Caporaso et al., 2010b).

Clean reads were subjected to primer sequences removal and clustering to generate operational taxonomic units (OTUs) using Vsearch software (Version 2.4.2) (Rognes et al., 2016) with a 97% similarity cutoff. The representative read of each operational taxonomic unit (OTU) was selected using the QIIME package. All representative reads were annotated and blasted against Unite database (ITSs rDNA) using pynast (v0.1) (Caporaso et al., 2010a).

Statistical Analysis
Statistical analysis of serum biochemical indexes and gene expression was processed using Graphpad Prism, version v8 (GraphPad Software, Inc., San Diego, United States). All experiments were repeated at least six times and the obtained data are presented as the mean ± standard deviation. The Student’s t-test was used for the analysis of statistical significance between two groups, and one-way analysis of variance followed by Tukey test was applied to analyze statistical significance across three groups or more. A p-value < 0.05 was considered to indicate a statistically significant difference.

RESULTS
Therapeutic Effects of ZYP on Serum Biochemistry, Liver Inflammation Markers, Cell Necrosis, Fibrosis Mediators, and Liver Histopathology
As shown in Figure 1, the cholestasis-induced rats exhibited a significant increase in serum ALT and AST levels, which were markedly reduced following treatment with high or low doses of ZYP. Similarly, the levels of TC, TBA, γ-GT, TBIL, the expression of TNF-α, TIMP-1, and the BAX/BCL-2 ratio were significantly increased in cholestasis-induced rats compared with the control
rats, and these changes were effectively alleviated following treatment with ZYP. In contrast, the expression of IL-10, GCLC and GCLM showed opposite results, while TGF-β showed no significant difference after ZYP intervention (Figures 1A–O). Representative photomicrographs of hematoxylin and eosin (HE)-stained liver tissue from control rats and the cholestasis rats with or without ZYP (0.6/1.2 g/kg) treatment are presented in Figures 1P–S. The Ishak scores are presented in Figure 1T. The morphology of liver lobules was normal in the control group, and the central veins and radiating hepatic cords were clearly visible. In contrast, rats with cholestasis exhibited significantly elevated inflammation and necrosis scores and significant changes in liver structure, including acute infiltration of polymorphonuclear neutrophils, nuclear deformation, and necrosis-induced inflammation. However, the cholestasis-induced rats treated with ZYP, especially the ZYP+ group, presented significantly reduced Ishak scores and exhibited only mild inflammatory infiltration of the central vein and portal area, and relatively milder bile duct epithelial damage.

**Multivariate Statistical Analysis of LC-MS**

PCA was used to compare the differences among all groups. As shown in Figure 2, a score plot allowed visualization of the observational clusters, which differed significantly between the control, model, ZYP−, ZYP+, and QC groups (Figures 2A,C–E). The results of the PCA indicated that multivariate statistical analysis was necessary to clarify the differences among the groups; therefore, OPLS-DA models were built to facilitate data interpretation.

OPLS-DA analysis was performed to obtain a deeper understanding of the differential metabolites, which were accountable for the intergroup separation. In this study, the control, model, ZYP−, and ZYP+ groups could be distinguished. The $R^2$X, $R^2$Y, and $Q^2$ (cum) of the model and control groups were 0.75, 0.997, and 0.953 respectively, as
FIGURE 2 | Multivariate statistical analysis of metabolic profiles derived from the Control, Model, ZYP−, and ZYP+ groups. (A) PCA score plot of the Control, Model, ZYP−, ZYP+ and QC groups; (B) Parameters of PCA; (C–E) PCA of Model vs Control group, ZYP− vs Model and ZYP+ vs Model, respectively; (F–H) OPLS-DA of the Model vs Control group, ZYP− vs Model and ZYP+ vs Model, respectively; (I–K) 200-permutation test of the Model vs Control group, ZYP− vs Model and ZYP+ vs Model, respectively; (L–N) OPLS-DA score plot of the Model vs Control group, ZYP− vs Model and ZYP+ vs Model, respectively.
compared with the values of 0.682, 0.996, 0.894 (ZYP− vs control), and 0.684, 0.993, 0.866 (ZYP+ vs model), respectively, of the ZYP−/ZYP+ and model groups (Figures 2F–H). To prevent overfitting of the model, the quality of the model was examined by seven-cycle interactive verification and 200-response ranking test. These results indicated that these OPLS-DA were not overfit and indicated that the OPLS-DA achieved high separating capacity (Figures 2I–K). The OPLS-DA loading scatter plot identified several critical variables that were distant from the center of the loading plot, suggesting that these critical variables were important variables for clustering (Figures 2L–N).
Metabolite Identification and Pathway Analysis in ZYP-treated Rats With Cholestasis

Differential metabolite levels were determined based on VIP values > 1 and adjusted p-values < 0.05. We identified a total of 1090 metabolites that were significantly differentially expressed between the Model and Control groups, and 965 and 734 significantly differentially expressed metabolites between ZYP– and Model group, and the ZYP+ and Model groups, respectively (Supplementary Data).

Based on the results of the serum biochemistry and liver histological examination, the ZYP+ group (1.2 g/kg) exhibited better effects than the ZYP– group (0.6 g/kg). Additionally, the dose of the ZYP+ group is that commonly used in clinical practice; thus for the reasons described above, it is worthy to focus specifically on this group. In the ZYP+ vs Model comparison, the subclasses of differential metabolites analysis was associated with amino acids, peptides, and analogues (37 differential metabolites), fatty acids, and conjugates (37 differential metabolites), and flavonoids (37 differential metabolites). The number and trend of metabolites in different groups were presented in a volcano plot (Figures 3A–C), and the Top 50 differential metabolites between the Control, Model, ZYP+, and ZYP– groups were presented as a heatmap (Figures 3D–F).

To determine the functions of the differential metabolites, pathway analysis was carried out to further identify potentially enriched pathways (p < 0.05) associated with model alterations or ZYP treatment intervention. The results of the significant pathway terms emerging in the Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were mapped onto a bubble graph (Figure 4). Activation of eight pathways was identified, specifically bile secretion, steroid hormone biosynthesis, choline metabolism in cancer, pathways in cancer, histidine metabolism, prostate cancer, pancreatic cancer, and tryptophan metabolism when compared to the Model vs Control groups and ZYP+ vs Model groups. The above results suggested that ZYP participated in above biological process and signaling pathways and generated significant beneficial effects as intervention of cholestasis.

Fecal Microbiota Analysis

To explore whether the effects of the ZYP extract were associated with changes in the fecal microbiota, we analyzed the fecal flora composition of rats after ANIT-induced cholestasis or ZYP treatment.

The OTUs at the 97% similarity level were obtained using cluster tags, as is shown in the OTUs-Venn diagram (Figure 5A). In total, 140 OTUs were shared by the Control, Model, ZYP– and ZYP+ groups, the information regarding species, genus, family, order, class, phylum and kingdom level for each sample is shown in Figure 5B.

Alpha diversity is widely used for the analysis of microbial community diversity. Good’s Diversity Index, the Shannon Diversity Index, and the species accumulation curves (SAC) of each group are shown in Figures 6A–C. The violin plots of the Good’s diversity Index and the Shannon Diversity Index suggest that treatment with oral ZYP (low dose or high dose) had no significant effects on the alpha diversity of the fecal microbiota in cholestasis-induced rats. The amount of sequencing data was sufficient to reflect most microbial information in the samples.

Beta diversity analysis defines the extent of similarities and differences among microbial communities. The results of the Non-metric Multidimensional Scaling (NMDS), Principal Coordinates Analysis (PCoA, unweighted_unifrac), and PCA analyses are shown in Figures 6D–F. The data of the beta diversity analysis revealed distinct differences in Control, Model, ZYP–, and ZYP+ groups, illustrating that oral ZYP (either low or high doses) had a significant effect on the microbiota of cholestasis rats.

To evaluate the differences in microbial diversity, one-way ANOVA was applied to identify significant alterations in the composition of the host fecal microbiota at the genus and the phylum levels during infection (Figures 7A,B), the results show that cholestasis and ZYP influenced species abundances. To filter which bacteria differed between the experimental groups, we conducted a LEfSe (linear discriminant analysis coupled with
FIGURE 5 | OTUs classification results. (A) Operational Taxonomic Units (OTUs) based petal maps; (B) Comment situation of tags.

FIGURE 6 | Alpha and beta diversity analysis of the OTUs. (A) Good diversity analysis; (B) Shannon diversity analysis; (C) Curve of SAC; (D) NMDS analysis; (E) PCoA analysis; (F) PCA analysis.
effect size measurements) analysis (Figure 7C). Overall, at the class and genus level, two classes and nine genera, specifically Prevotellaceae_Ga6A1_group, uncultured_bacterium, Alloprevotella, gut_metagenome, Lactobacillus, Bacteroides, Gammaproteobacteria, Actinobacteria, and Alistipes, were found to have significant differences. Of these, Lactobacillus, Bacteroides, Gammaproteobacteria, and Actinobacteria were the most representative bacteria in the ZYP+ treatment group. The above information is shown in Figure 7D.

Potential Relationships Between Biochemical Indexes, Fecal Metabolites, and Fecal Microbiota

To comprehensively analyze the relationships between biochemical indexes, fecal metabolites, and the genera of fecal microbiota, a correlation matrix was established calculating Spearman’s correlation coefficient. As shown in Figures 8A,B, the pairwise correlation between the Model vs Control and the ZYP+ vs Model groups showed consistently strong correlations between intestinal microorganism and fecal metabolites. Furthermore, six biochemical indices, (ALT, AST, and γ-GT), TC, TBA, and TBIL are important indices of the clinical manifestations of cholestatic hepatitis (Bouchier and Pennington, 1978; Gomez Selgas et al., 2014; Wu et al., 2021). TNF-α, IL-10, TIMP-1, GCLC, GCLM, BCL2, and BAX are common indicators used to evaluate the inflammatory response, oxidative stress, apoptosis, and fibrosis (Yamazaki, 1994; Golbar et al., 2017; Strasser and Vaux, 2018). The results of the present study suggested that ZYP, especially high-doses of ZYP (1.2 g/kg/d) could represent a potential anti-

DISCUSSION

Cholestasis is a widespread clinical liver disease which requires new therapeutic options. In clinical practice, ZYP is an effective combination medicine for cholestasis treatment. The purpose of this study was to determine the therapeutic effects of ZYP on cholestasis, and to elucidate the related mechanisms by metabolomics and intestinal flora profiling.

Serum liver enzymes (including ALT, AST, and γ-GT), TC, TBA, and TBIL are important indices of the clinical manifestations of cholestatic hepatitis (Bouchier and Pennington, 1978; Gomez Selgas et al., 2014; Wu et al., 2021). TNF-α, IL-10, TIMP-1, GCLC, GCLM, BCL2, and BAX are common indicators used to evaluate the inflammatory response, oxidative stress, apoptosis, and fibrosis (Yamazaki, 1994; Golbar et al., 2017; Strasser and Vaux, 2018). The results of the present study suggested that ZYP, especially high-doses of ZYP (1.2 g/kg/d) could represent a potential anti-
inflammatory, antioxidant, anti-fibrosis and anti-apoptosis effects. Furthermore, a clear improvement in liver damage was observed following ZYP treatment. Overall, these results indicated that ZYP could represent a potential therapeutic drug with protective effects against ANIT-induced cholestasis or following liver injury.

The diversity of fecal bacteria is associated with alterations and of the gut microbiome, and is often correlated with metabolism and immunity in patients with primary biliary cirrhosis (Lv et al., 2016; Wang et al., 2019). To explore the relevant fecal bacteria associated with ZYP treatment and cholestasis, we used 16S microbiome sequencing, which provides a measure of relative but not absolute bacterial abundance. In this study, we determined that *Lactobacillus*, *Bacteroides*, *Gammaproteobacteria*, and *Actinobacteria* were the most representative bacteria in the ZYP+ group (Figure 7). Thus,
we hypothesized two possible explanations for the diversity observed in the Model and ZYP+ groups. First, most of the representative bacteria in the ZYP+ group, which may contribute to higher diversity, were beneficial bacteria, and were enhanced in the cholestasis Model group, such as Lactobacillus, Bacteroidetes, and Actinobacteria. Of these, bacteria of the Lactobacillus genus have been shown to increase resistance against environmental stresses, and are sensitive or weakly tolerant to acidic environments and bile acid.

Bacteroidetes and Lactobacillus express bile salt hydrolase (BSH) and are involved in the metabolism of bile (Han et al., 2017; Chen et al., 2020). Actinobacteria has been implicated in the modulation of gut permeability, the immune system, metabolism, and the gut-brain axis (Binda et al., 2018). Further, Bacteroidetes and Lactobacillus may be associated with elevated levels of bile acids, and the enhanced expression of Actinobacteria may be associated with immune-inflammatory and autoimmune response by inducing regulatory T-cells (O’Mahony et al., 2008; Lyons et al., 2010). High doses of ZYP enhance the expression of the above bacteria, which indicated an improvement in the expression of BSH or T cell activity; thus, the promotion of bile metabolism may partly explain the interventional mechanism of ZYP in cholestasis. Second, Gammaproteobacteria, a class of pathogenic bacteria, may exhibit detrimental potential and cause abnormal inflammatory activation (Williams et al., 2010), however, it also considered as survival tool for bacteria in the environment (Vazquez-Rosas-Landa et al., 2017). In this study, ZYP enhanced the expression of Gammaproteobacteria, which allows us to speculate that bacteria–bacteria interactions may play a role in the interventional mechanism of ZYP in cholestasis. However, the detailed mechanisms involved remain to be further explored.

Untargeted metabolomics may contribute to provide evidence that fecal microbiota metabolites infer host-microbiome co-metabolic effects (Griffiths et al., 2010), and may help further explain the potential mechanisms of ZYP in cholestasis. The metabolomes of fecal samples were analyzed via an untargeted LC-MS-based metabolomics approach. We identified 1090, 965, and 734 metabolites as differential metabolites between the Model vs Control, ZYP+ vs Model, and ZYP+ vs Model group comparisons, respectively. To explore the underlying biological mechanisms and relationships involved in the differential production of these metabolites, we applied KEGG pathway analysis. As a result, eight pathways, namely bile secretion, steroid hormone biosynthesis, choline metabolism in cancer, pathways in cancer, histidine metabolism, prostate cancer, pancreatic cancer, and tryptophan metabolism were enriched when compared to metabolites generated by the Model vs Control and ZYP+ vs Model groups. Among these metabolic pathways, bile secretion plays a vital role in the health of an organism and blockage of bile secretion leads to cholestasis (Jia et al., 2020).

Recent studies have shown that steroid hormone biosynthesis involves the coordinate activity of several members of the cytochrome P450 superfamily of monoxygenases and is associated with fatty-acid degradation (Li et al., 2012; Zhao et al., 2019). Histidine metabolism and tryptophan metabolism also undergo amino acid metabolism. Previous studies have confirmed that amino acid metabolism has a clear correlation with cholestasis, as amino acids are the main precursors of glutathione biosynthesis (Yu et al., 2018; Li et al., 2019). Further, amino acid metabolism interferes with cholestasis by affecting glutathione synthesis and thus produces antioxidant stress, which is supported by other study showing that γ-GT catalyzes biliary glutathione and expands the pool of amino acid precursors required for conjugation (glycine directly and taurine through cysteine oxidation) (Chen MF. et al., 2019).

However, in our study, correlation analysis between metabolomics and γ-GT showed that there was no significant correlation between the two in the ZYP+ vs model groups (Figure 8D); thus, the detailed mechanisms remain to be further explored. Altogether, the above findings suggest that perturbation of these metabolic pathways may act to improve metabolic activity, which ultimately explains the beneficial effects on cholestasis by ZYP intervention. In addition, the pathways in cancer, prostate cancer, pancreatic cancer, and choline metabolism in cancer were perturbed when comparing the Model vs Control groups and ZYP+ vs Model groups, which indicated that ZYP may also be promising as a potential anticancer agent.

To comprehensively analyze the relationships between biochemical indices, changes in the inflammatory response, apoptosis, and gene expression associated with fibrosis, fecal metabolites, and the impact on the genera of fecal microbiota, a correlation matrix was established using Spearman’s correlation coefficient analysis. Our findings confirmed a mutual effect between the biochemical indices, gene expression associated with liver injury, fecal metabolites, and fecal microbial genera, which suggested an underlying reciprocal relationship among these factors.

**CONCLUSION**

In summary, the results of the present study demonstrated that ZYP exerts significant anti-cholestatic effects through a synergistic effect on fecal metabolism and fecal microbes. We also revealed that the altered fecal microbial composition achieved following ZYP treatment was marked by an increase of beneficial bacteria (Bacteroidetes, Lactobacillus and Actinobacteria) and pathogenic bacteria (Gammaproteobacteria) compared with the Model group, bacteria–bacteria interactions may play a role in the interventional mechanism of ZYP in cholestasis. In addition, oral administration of high-doses of ZYP also exerted a significant influence on fecal metabolomics against cholestasis in the rat, which might be associated with amino acid metabolism, steroid hormone biosynthesis, and bile secretion. These findings highlight that ZYP, an ancient classic formulation of Coptis-Evodia herb couple, may prevent cholestasis. Future research will improve the understanding of ZYP’s mechanisms and the pharmacological rationale underlying its therapeutic application.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and
accession number(s) can be found below: NCBI [accession: PRJNA720504]; Metabolights [accession: MTBLS2721].

ETHICS STATEMENT

The animal study was reviewed and approved by Ethics Committee of Chengdu University of Traditional Chinese Medicine.

AUTHOR CONTRIBUTIONS

TS and YW conceived and designed the study. HY acquired, analyzed, interpreted the data, and prepared the manuscript. CL was responsible for handling the animals and obtaining tissue specimens. FZ, JW, JH, and XZ performed statistical analyses. All authors have read and approved the final version of this manuscript.

FUNDING

The current work was supported by the China Postdoctoral Science Foundation (no. 2020M683641X), “Xinglin Scholar” discipline talents Research Enhancement “Programme of Chengdu University of Traditional Chinese Medicine (no. BSH2019020), National Natural Science Foundation Project of China (no. 81973743), Science and Technology Department Project of Sichuan Province (no. 20MZGC0241) and Social Science 13th Five-Year Plan Project of Sichuan Province (no. SC18KP029).

ACKNOWLEDGMENTS

The authors would like to thank the staff of the Experimental Center of Integrated Chinese and Western Medicine of Chengdu University of Traditional Chinese Medicine (Chengdu, China), Shanghai OE Biotech, Inc. (Shanghai, China), and Doctors Zongying Xu, Zhiheng Zheng and Dingnan Wang for their technical support.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.695035/full#supplementary-material

REFERENCES

Allen, K., Jaeschke, H., and Coppole, B. L. (2011). Bile Acids Induce Inflammatory Genes in Hepatocytes: A Novel Mechanism of Inflammation During Obstructive Cholestasis. Am. J. Pathol. 178 (1), 175–186. doi:10.1016/j.ajpath.2010.11.026

Beuers, U., Boyer, J. L., and Paumgartner, G. (1998). Ursodeoxycholic Acid in Cholestasis: Potential Mechanisms of Action and Therapeutic Applications. Hepatology 28 (6), 1449–1453. doi:10.1002/hep.510280601

Binda, C., Lopetuso, L. R., Rizzatti, G., Ghibili, G., Cennamo, V., and Gasbarrini, A. (2018). Actinobacteria: A Relevant Minority for the Maintenance of Gut Homeostasis. Dig. Liver Dis. 50 (5), 421–428. doi:10.1016/j.dld.2018.02.012

Bolger, A. M., Lohse, M., and Usadel, B. (2014). Trimmomatic: A Flexible Trimmer for Illumina Sequence Data. Bioinformatics 30 (15), 2114–2120. doi:10.1093/bioinformatics/btu170

Bouchier, I. A., and Pennington, C. R. (1978). Serum Bile Acids in Hepatobiliary Disease. Gut 19 (6), 492–496. doi:10.1136/gut.19.6.492

Boyer, J. L. (2007). New Perspectives for the Treatment of Cholestasis Lessons from Basic Science Applied Clinically. J. Hepatol. 46 (3), 365–371. doi:10.1016/j.jhep.2006.12.001

Caporaso, J. G., Bittinger, K., Bushman, F. D., DeSantis, T. Z., Andersen, G. L., and Knight, R. (2010a). PyNAST: A Flexible Tool for Aligning Sequences to a Template Alignment. Bioinformatics 26 (2), 266–267. doi:10.1093/bioinformatics/btp636

Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., et al. (2010b). QIIME Allows Analysis of High-Throughput Community Sequencing Data. Nat. Methods 7 (5), 335–336. doi:10.1038/nmeth.f.303

Chatterjee, A., Mukherjee, S., Basu, B., Roy, D., Basu, R., Ghosh, H., et al. (2020). Insight into the Distinctive Paradigm of Human Cytomegalovirus Associated Intrahepatic and Extrahepatic Cholestasis in Neonates. Sci. Rep. 10 (1), 15861. doi:10.1038/s41598-020-73009-z

Chen, Z., Zhu, Y., Zhao, Y., Ma, X., Niu, M., Wang, J., et al. (2016). Serum Metabolomic Profiling in a Rat Model Reveals Protective Function of Paconofillorin Against ANIT Induced Cholestasis. Phytother Res. 30 (4), 654–662. doi:10.1002/ptr.5575

Chen, C., Yin, Q., Wu, H., Cheng, L., Kwon, J. I., Jin, J., et al. (2019a). Different Effects of Premature Infant Formula Breast and Milk on Infant Microcolordial Development in Premature Infants. Front. Microbiol. 10, 3020. doi:10.3389/fmicb.2019.03020

Chen, M. F., Gong, F., Zhang, Y. Y., Li, C., Zhou, C., Hong, P., et al. (2019b). Preventive Effect of YGDEY from Tilapia Fish Skin Gelatin Hydrolysates Against Alcohol-Induced Damage in HepG2 Cells Through ROS-Mediated Signaling Pathways. Nutrients 11 (2), 392. doi:10.3390/nu11020392

Chen, X., Wu, Y., Hu, Y., Zhang, Y., and Wang, S. (2020). Lactobacillus Rhamnosus GG Reduces β-cyclocinnin-Allergy-Induced Apoptotic Cells by Regulating Bacteroides and Bile Secretion Pathway in Intestinal Contents of BALB/c Mice. Nutrients 13 (1), 55. doi:10.3390/nu13010055

Cheng, D. H., Zhao, Y. L., and Yang, H. B. (2011). Effect of Zuojin Pill and Fanzuojin Pill on the Growth Metabolism of Enterobacteria by Microcalorimetry. Zhongguo Zhong Xi Yi Jie He Za Zhi 31 (2), 209–212. doi:10.1088/1009-0630/13/1/25

Cheng, J., Wang, J., Zhang, W., Yang, X., and Cao, Y. (2015). A Cross-Sectional Study on Intrahepatic Cholestasis Indicators of Viral Hepatitis Patients. J. Hepatol. 62 (Suppl. 2), S538. doi:10.1016/S0168-8278(15)30798-4

Crosignani, A., Setchell, K. D., Invernozzi, P., Langhi, A., Rodrigues, C. M., and Podda, M. (1996). Clinical Pharmacokinetics of Therapeutic Bile Acids. Clin. Pharmacokinet. 30 (5), 333–358. doi:10.2165/00003088-199630050-00002

Golbar, H. M., Izawa, T., Bondoc, A., Wijesundera, K. K., Tennakoon, A. H., Kuwamura, M., et al. (2017). Attenuation of Alpha-Naphthilisothiocyanate (ANIT)-induced Biliary Fibrosis by Depletion of Hepatic Macrophages in Rats. Exp. Toxicol. Pathol. 69 (4), 221–230. doi:10.1016/j.etp.2017.01.005

Gomez Selgas, A., Bexfield, N., Scase, T. J., Holmes, M. A., and Watson, P. (2014). Total Serum Bilirubin as a Negative Prognostic Factor in Idiopathic Canine Chronic Hepatitis. J. Vet. Diagn. Invest. 26 (2), 246–251. doi:10.1177/1040638715520062

Goodman, Z. D. (2007). Grading and Staging Systems for Inflammation During Obstructive Cholestasis: Potential Mechanisms of Action and Therapeutic Applications. Hepatology 28 (6), 1449–1453. doi:10.1002/hep.510280601

Griffiths, W. J., Koal, T., Wang, Y., Kohl, M., Enot, D. P., and Deigner, H. P. (2010). Targeted Metabolomics for Biomarker Discovery. Angew. Chem. Int. Ed. Engl. 49 (32), 5426–5445. doi:10.1002/anie.200905579

Guo, W., Huang, J., Wang, N., Tan, H. Y., Cheung, F., Chen, F., et al. (2019). Integrating Network Pharmacology and Pharmacological Evaluation for Deciphering the Action Mechanism of Herbal Formula Zuojin Pill in Suppressing Hepatocellular Carcinoma. Front. Pharmacol. 10, 1185. doi:10.3389/fphar.2019.01185

Han, K., Bose, S., Wang, J. H., Lim, S. K., Chin, Y. W., Kim, Y. M., et al. (2017). In Vivo Therapeutic Effect of Combination Treatment with Metformin and Scutellaria Baicalensis on Maintaining Bile Acid Homeostasis. PLoS One 12 (9), e0182467. doi:10.1371/journal.pone.0182467
